Shell Asset Management’s Myriad Genetics MYGN Stock Holding History

Shell Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,203	Closed	-$380K	–	1478
2020 Q4	$380K	Hold	19,203	–	–	0.01%	907
2020 Q3	$250K	Hold	19,203	–	–	0.01%	973
2020 Q2	$218K	Buy	19,203 +3,228	+20%	+$45.8K	0.01%	1006
2020 Q1	$229K	Sell	15,975 -243	-1%	-$5.13K	0.01%	968
2019 Q4	$442K	Sell	16,218 -413	-2%	-$11.4K	0.01%	945
2019 Q3	$476K	Sell	16,631 -144	-0.9%	-$4.2K	0.01%	917
2019 Q2	$466K	Sell	16,775 -383	-2%	-$10.8K	0.01%	944
2019 Q1	$570K	Hold	17,158	–	–	0.01%	854
2018 Q4	$499K	Sell	17,158 -1,400	-8%	-$50.4K	0.01%	845
2018 Q3	$854K	Hold	18,558	–	–	0.02%	747
2018 Q2	$694K	Sell	18,558 -996	-5%	-$33.6K	0.01%	836
2018 Q1	$578K	Hold	19,554	–	–	0.01%	870
2017 Q4	$672K	Hold	19,554	–	–	0.01%	814
2017 Q3	$707K	Sell	19,554 -21,292	-52%	-$607K	0.02%	736
2017 Q2	$1.05M	Hold	40,846	–	–	0.02%	610
2017 Q1	$784K	Sell	40,846 -2,860	-7%	-$50.7K	0.02%	747
2016 Q4	$729K	Sell	43,706 -381	-0.9%	-$6.89K	0.02%	768
2016 Q3	$907K	Sell	44,087 -2,017	-4%	-$51.2K	0.02%	685
2016 Q2	$1.41M	Sell	46,104 -2,623	-5%	-$91.1K	0.03%	487
2016 Q1	$1.82M	Sell	48,727 -2,916	-6%	-$110K	0.04%	400
2015 Q4	$2.23M	Sell	51,643 -3,224	-6%	-$136K	0.05%	353
2015 Q3	$2.12M	Buy	54,867 +2,553	+5%	+$90.6K	0.03%	447
2015 Q2	$1.78M	Sell	52,314 -2,391	-4%	-$81.3K	0.04%	458
2015 Q1	$1.94M	Sell	54,705 -162	-0.3%	-$5.8K	0.03%	467
2014 Q4	$1.87M	Hold	54,867	–	–	0.03%	495
2014 Q3	$2.12M	Buy	54,867 +5,109	+10%	+$191K	0.03%	460
2014 Q2	$1.94M	Sell	49,758 -579	-1%	-$21.5K	0.03%	504
2014 Q1	$1.72M	Sell	50,337 -204	-0.4%	-$6.32K	0.03%	549
2013 Q4	$1.06M	Buy	50,541 +8,173	+19%	+$207K	0.02%	675
2013 Q3	$996K	Hold	42,368	–	–	0.02%	705
2013 Q2	$1.14M	Buy	+42,368	New	+$1.23M	0.02%	663

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Shell Asset Management's MYGN Position: Q1 2021 in Review

Shell Asset Management sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 19,203 shares — an estimated $380K sold.

Shell Asset Management first reported a position in MYGN in Q2 2013 and held it in 31 quarters. The position peaked at $2.23M in Q4 2015. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

Shell Asset Management reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
Shell Asset Management sold 19,203 Myriad Genetics shares in Q1 2021, an estimated $380K.
Shell Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 31 quarters.
Shell Asset Management's Myriad Genetics position peaked at $2.23M in Q4 2015.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.